The Treatment Algorithms Insight Series delivers real value by examining physicians’ actual prescribing behavior as they initiate therapy and move through second- and third-line choices. Our analysis is supported by a deep longitudinal patient-level claims dataset, and provides a representative sample of U.S. treatment practice for Medicare supplemental and commercially insured patients. The claims are less than 6 months old at the time of publication.
report is updated quarterly and is delivered in three parts:
Findings PowerPoint Deck: includes expert insight and analysis of quarterly
Algorithms Dashboard: online interactive platform allows users to quickly
maneuver to and view their data of interest.
Data File: includes underlying data for key graphs and tables.
- Patients age 18 or older who are continuously enrolled for the complete two-year study period must meet one of the following conditions:
* At least one prescription from the drug list and at least one claim with a diagnosis code for Type 2 Diabetes (International Classification of Diseases, Ninth Revision [ICD-9] diagnostic codes 250.00, 250.02, 250.10, 250.12, 250.20, 250.22, 250.30, 250.32, 250.40, 250.42, 250.50, 250.52, 250.60, 250.62, 250.70, 250.72, 250.80, 250.82, 250.90, 250.92) during the study period. OR
* At least two claims with any of the above diagnosis codes for Type 2 Diabetes in the two-year period (both claims must be at least 30 days apart) OR
* At least one claim with any of the above diagnosis codes for Type 2 Diabetes in the two-year period and at least two laboratory codes for an HbA1c test (CPT 83036) in the second year of the study period only OR
* At least one prescription for an oral antidiabetic agent and one prescription for either insulin or Symlin
* Patients between the ages of 18 and 40 who receive a prescription for either insulin or Symlin but do not receive an oral antidiabetic agent are excluded from the Type 2 Diabetes analysis as these patients are highly likely to have Type 1 Diabetes. Although Type 1 Diabetes patients older than the age of 40 could potentially be captured in our analysis, we strongly believe that the vast majority of sampled patients are accurately diagnosed with Type 2 Diabetes.
Newly Diagnosed Patients:
share by drug class and key products across three lines of therapy, within
one year of diagnosis
flow chart through one year of treatment for all first-line products,
including progression rates and add/switch behavior
and key concomitant therapies by line of therapy
trending of patient share by line of therapy
snapshot of patient share by drug class and key products
to key therapy flowcharts tracking the preceding therapy patterns for all
key therapies, including add/switch behavior
source of business including share for continuing, new (switches/adds), new
(initial therapy) business
and key concomitant therapies
trending of patient share for all key therapies.